⌕
Arcturus Therapeutics Holdings · ARCT · Nasdaq
Tenet 61 · Solid
Compare
$8.31−0.60%At closeTenet 61 · Solid
$8.31−0.05 (−0.60%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Arcturus Therapeutics Holdings (ARCT) Earnings Forecast

Analysts expect Arcturus Therapeutics Holdings (ARCT) to lose $2.93 a share in FY26, the average of 7 estimates as of Nov 17, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
FY26 consensus EPS
$−2.93
7 analysts
FY27 consensus EPS
$−3.50
9 analysts · low $−3.82, high $−3.04
Disagreement, FY26
$0.84
wide, $−3.43 to $−2.59

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 17, 2026 · we check it nightly

Analysts expect Arcturus Therapeutics Holdings to earn $2.99 a share in FY30; 3 analysts publish an estimate for FY30.

Forward P/E · FY26E
n/m
a multiple of a loss is not meaningful
Revisions
Starts tonight
a revision needs two nights of one fiscal period to compare
Coverage · FY26
7 · 7
EPS estimates · revenue estimates

Are estimates going up or down lately?

Our record of this company's consensus starts with tonight's snapshot. A revision needs two of our own nightly snapshots of one fiscal period to compare, and nothing before the first is reconstructed, because a backfilled revision is a number we never observed.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price at last close · consensus as of Nov 17, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from FY30 on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY30
$0.1B
3 analysts · low $0.0B, high $0.3B · thin coverage
Multiple · five-year average P/E
48.1×
Average of the fiscal-year P/Es, FY22 to FY22.
×
Receipt · ARCT · FY30Nov 17, 2026
Implied, a share
Waiting

We hold no net cash and no diluted share count for this company, so an EBITDA multiple cannot be bridged to a price a share here. The sum stops rather than guessing the bridge.

Drag the multipleShaded: where Arcturus Therapeutics Holdings' P/E sat at each fiscal year end, FY22 to FY22. Each dot is one year.
43×44×46×48×50×52×53×
5-yr avg 48.1×10-yr median 48.1×

Each point on the line is a multiple, and the flag is the price it implies for FY30. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY26, so there is neither a multiple of those earnings to pay nor a rate to grow from.

How much do analysts disagree?

For FY30, estimates run from $0.67 to $8.62 around an average of $2.99, drawn by 3 analysts.

FY26E7 analysts
$−3.43 to $−2.59 · $0.84 wide
FY27E9 analysts
$−3.82 to $−3.04 · $0.78 wide
FY28E9 analysts
$−4.16 to $−2.48 · $1.68 wide
FY29E3 analysts
$−3.02 to $−0.23 · $2.79 wide
FY30E3 analysts
$0.67 to $8.62 · $7.95 wide

The dashed line is FY25 filed $−2.40, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Arcturus Therapeutics Holdings to lose $0.82 a share in the December quarter, the average of 6 estimates. We hold no expected date for the next report.

0
$−1.05
$−0.82high $−0.67
low $−0.95
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 6 analysts
Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$3,875.2K
7 analysts, 1,614.7 to 8,477.1 in $K · 7,197.0 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. For the March quarter, analysts expect a loss of $0.91 a share.

Does Arcturus Therapeutics Holdings usually beat or miss?

We have not been able to check a quarter yet. We hold no estimate for Arcturus Therapeutics Holdings yet, so this record starts on the night we first do.

Before our record
Mar '26
Jun '26
Sep '26
Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. A quarter we did not hold an estimate for is never filled in after the fact.

The Street expects sales to grow −3.2% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

7 analysts publish an EPS estimate for FY26 and 7 publish revenue. Coverage thins with distance: 3 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by yearHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
77
FY26E
99
FY27E
109
FY28E
53
FY29E
53
FY30E

The full consensus, year by year

Consensus as of Nov 17, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
−0.00.40.8historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 7 revenue estimates for FY26, 5 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−4.922.109.13historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 7 EPS estimates for FY26, 3 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.1—−2.40————as filedn/m
FY26E0.00.0 to 0.0▼68.5%a−2.93−3.43 to −2.59n/ca−0.1−0.10.037 · 7n/m
FY27E0.00.0 to 0.1▼3.2%−3.50−3.82 to −3.04—−0.1−0.10.039 · 9n/m
FY28E0.00.0 to 0.0▲75.8%−3.35−4.16 to −2.48—−0.1−0.10.0310 · 9n/m
FY29E0.20.1 to 0.4n/cb−1.05−3.02 to −0.23n/cb−0.0−0.00.035 · 3n/m
FY30E0.30.1 to 0.8▲120.6%2.990.67 to 8.62—0.10.10.035 · 32.8×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 7 EPS estimates for FY26. Not investment advice.

What do analysts expect Arcturus Therapeutics Holdings to earn in FY26?

Analysts expect Arcturus Therapeutics Holdings to lose $2.93 a share in FY26, the average of 7 estimates as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.